Aprea Therapeutics Reports Widening Q3 Net Loss
The biotech company reported a $4.81 million net loss for the quarter ended September 30, 2026, up from $2.97 million a year earlier.
Updated on Nov. 6, 2026 in Corporate Finance
Aprea Therapeutics posted a third-quarter 2026 net loss of $4.81 million, compared with $2.97 million in the same period of 2025. The company also expanded its APR-1051 Phase 1 trial to nine active sites.
Why it matters
The larger loss reflects higher research and development spending, mainly tied to the APR-1051 Phase 1 study of this oral WEE1 inhibitor. Aprea has not commercialized any product candidates, so its results depend on clinical progress and funding.
Research and development expenses rose to $3.34 million from $1.64 million a year earlier, with cash and equivalents at $37.85 million on September 30, 2026. Weighted-average shares increased to 53.68 million from 6.37 million, partly due to 39.8 million shares issuable through nominal-consideration warrants, and the filing does not address how these will affect future per-share results.
The players
Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biopharmaceutical company developing oral WEE1 inhibitors for cancer treatment and has not yet commercialized any product candidates.
The details
Aprea's loss per share narrowed to $0.09 from $0.47 because the weighted-average share count rose sharply, even though total losses increased. The company is advancing ACESOT-1051, a Phase 1 study of APR-1051, and expects to complete dose escalation and backfill expansion enrollment in the second quarter of 2027.
Timeline
Dec. 31, 2025: Cash and equivalents balance comparison point
Sept. 30, 2026: Third quarter ended with the reported net loss
Q4 2026: Target enrollment pace of six to 10 patients monthly
Nov. 20, 2026: Updated interim results presented at the EORTC-NCI-AACR Symposium in Barcelona
Market Dynamics
Aprea's trial updates are presented at the EORTC-NCI-AACR Symposium, a long-running forum for molecular targets and cancer therapeutics, where its WEE1 inhibitor data joins other early-stage oncology findings. Its shrinking per-share loss despite rising total losses reflects the dilution common among clinical-stage biotechs that rely on equity and warrant financing.
Shareholders in Aprea face dilution, since the weighted-average share count rose from 6.37 million to 53.68 million and warrants could add 39.8 million more. The company's projected cash runway into early 2028 gives investors a defined window to judge whether the APR-1051 trial advances.
The takeaway
For investors tracking clinical-stage biotechs, the key signal is whether falling per-share losses reflect real progress or simply a larger share base. Watch Aprea's enrollment and dose-escalation milestones in 2027 to see whether the spending is producing results.
What happens next
Aprea expects to complete dose escalation and backfill expansion enrollment in the second quarter of 2027, with its operating plan projected to cover cash needs into the first quarter of 2028.
Further reading
Explore more Corporate Finance coverage for context on how biotech firms manage losses and dilution.
Source note: This article includes information reported by TokenPost.
